As of May 02
| -0.03 / -1.27%|
The 3 analysts offering 12-month price forecasts for Repros Therapeutics Inc have a median target of 2.00, with a high estimate of 3.50 and a low estimate of 1.00. The median estimate represents a -14.53% decrease from the last price of 2.34.
The current consensus among 4 polled investment analysts is to Hold stock in Repros Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.